H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 20 from EUR 13 and keeps a Buy rating on the shares after the company presented clinical data updates from two ongoing Phase 1 studies with JNJ-1900. The key data was the systemic overall response rate of 32% achieved by Cohort 1 and 37% by Cohort 2, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix Reports Promising Phase 1 Results for Esophageal Cancer Treatment
- Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts
- Nanobiotix Reports Half-Year 2025 Financial Results and Strategic Progress
- Nanobiotix Releases Half-Year Financial Report Highlighting JNJ-1900 Developments
- Nanobiotix Reveals Promising Phase 1 Results for JNJ-1900 in Cancer Treatment